Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Furling

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
The Journal of Clinical Investigation|September 4, 2019
Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and miceArnaud F Klein, Miguel A Varela, Ludovic Arandel, et al.
Plos Genetics|December 5, 2012
Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locusAline Huguet, Fadia Medja, Annie Nicole, et al.
The Journal of Clinical Investigation|July 16, 2004
Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscleYvan Torrente, Marzia Belicchi, Maurilio Sampaolesi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
CRISPR/Cas9-Induced (CTG⋅CAG)<sub>n</sub> Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome EditingEllen L van Agtmaal, Laurène M André, Marieke Willemse, et al.
Molecular Therapy. Nucleic Acids|November 4, 2015
In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide MetforminDelphine Laustriat, Jacqueline Gide, Laetitia Barrault, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophySusan A M Mulders, Walther J A A van den Broek, Thurman M Wheeler, et al.
Nature Structural & Molecular Biology|June 21, 2011
Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophyFrédérique Rau, Fernande Freyermuth, Charlotte Fugier, et al.
Neuropathology and Applied Neurobiology|December 28, 2022
MBNL-dependent impaired development within the neuromuscular system in myotonic dystrophy type 1Julie Tahraoui-Bories, Antoine Mérien, Anchel González-Barriga, et al.
JAMA Neurology|February 7, 2018
Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1Karim Wahbi, Raphaël Porcher, Pascal Laforêt, et al.
Human Molecular Genetics|November 2, 2013
High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell linesAmi Ketley, Catherine Z Chen, Xin Li, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
The Journal of Clinical Investigation|September 4, 2019
Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient-derived cells and miceArnaud F Klein, Miguel A Varela, Ludovic Arandel, et al.
Plos Genetics|December 5, 2012
Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locusAline Huguet, Fadia Medja, Annie Nicole, et al.
The Journal of Clinical Investigation|July 16, 2004
Human circulating AC133(+) stem cells restore dystrophin expression and ameliorate function in dystrophic skeletal muscleYvan Torrente, Marzia Belicchi, Maurilio Sampaolesi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|January 28, 2017
CRISPR/Cas9-Induced (CTG⋅CAG)<sub>n</sub> Repeat Instability in the Myotonic Dystrophy Type 1 Locus: Implications for Therapeutic Genome EditingEllen L van Agtmaal, Laurène M André, Marieke Willemse, et al.
Molecular Therapy. Nucleic Acids|November 4, 2015
In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide MetforminDelphine Laustriat, Jacqueline Gide, Laetitia Barrault, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 12, 2009
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophySusan A M Mulders, Walther J A A van den Broek, Thurman M Wheeler, et al.
Nature Structural & Molecular Biology|June 21, 2011
Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophyFrédérique Rau, Fernande Freyermuth, Charlotte Fugier, et al.
Neuropathology and Applied Neurobiology|December 28, 2022
MBNL-dependent impaired development within the neuromuscular system in myotonic dystrophy type 1Julie Tahraoui-Bories, Antoine Mérien, Anchel González-Barriga, et al.
JAMA Neurology|February 7, 2018
Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1Karim Wahbi, Raphaël Porcher, Pascal Laforêt, et al.
Human Molecular Genetics|November 2, 2013
High-content screening identifies small molecules that remove nuclear foci, affect MBNL distribution and CELF1 protein levels via a PKC-independent pathway in myotonic dystrophy cell linesAmi Ketley, Catherine Z Chen, Xin Li, et al.
Pageof 8